Lumos Pharma, Inc. (LUMO): Price and Financial Metrics
GET POWR RATINGS... FREE!
LUMO Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for LUMO is 0 -- better than merely 6.24% of US stocks.
- The ratio of debt to operating expenses for Lumos Pharma Inc is higher than it is for about merely 6.64% of US stocks.
- LUMO's price/sales ratio is 358.33; that's higher than the P/S ratio of 98.98% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Lumos Pharma Inc are BYSI, RDUS, INSM, INFN, and KPTI.
- LUMO's SEC filings can be seen here. And to visit Lumos Pharma Inc's official web site, go to www.lumos-pharma.com.
LUMO Valuation Summary
- In comparison to the median Healthcare stock, LUMO's price/sales ratio is 6344.93% higher, now standing at 731.5.
- Over the past 119 months, LUMO's price/sales ratio has gone up 681.4.
- Over the past 119 months, LUMO's EV/EBIT ratio has gone up 7.9.
Below are key valuation metrics over time for LUMO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| LUMO | 2021-08-31 | 731.5 | 0.9 | -5.1 | 0.7 |
| LUMO | 2021-08-30 | 715.3 | 0.9 | -4.9 | 0.7 |
| LUMO | 2021-08-27 | 708.9 | 0.9 | -4.9 | 0.8 |
| LUMO | 2021-08-26 | 683.9 | 0.8 | -4.7 | 0.9 |
| LUMO | 2021-08-25 | 671.0 | 0.8 | -4.6 | 1.0 |
| LUMO | 2021-08-24 | 644.4 | 0.8 | -4.5 | 1.1 |
LUMO Growth Metrics
- Its 2 year cash and equivalents growth rate is now at -40.36%.
- Its 2 year price growth rate is now at -70.56%.
- Its 5 year price growth rate is now at -90.63%.
The table below shows LUMO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.23 | -29.648 | -30.43 |
| 2021-09-30 | 0.05 | -30.8 | -27.204 |
| 2021-06-30 | 0.124 | -23.368 | -17.951 |
| 2021-03-31 | 0.147 | -30.099 | -14.634 |
| 2020-12-31 | 0.168 | -22.997 | -6.314 |
| 2020-09-30 | 0.561 | -24.048 | -12.17 |
LUMO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- LUMO has a Quality Grade of D, ranking ahead of 21.86% of graded US stocks.
- LUMO's asset turnover comes in at 0.001 -- ranking 434th of 681 Pharmaceutical Products stocks.
- INVA, RETA, and SUPN are the stocks whose asset turnover ratios are most correlated with LUMO.
The table below shows LUMO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.001 | 1 | -1.992 |
| 2021-03-31 | 0.001 | 1 | -0.861 |
| 2020-12-31 | 0.001 | 1 | -0.498 |
| 2020-09-30 | 0.004 | 1 | -0.644 |
| 2020-06-30 | 0.005 | 1 | -1.373 |
| 2020-03-31 | 0.007 | 1 | -2.610 |
LUMO Price Target
For more insight on analysts targets of LUMO, see our LUMO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
LUMO Stock Price Chart Interactive Chart >
LUMO Price/Volume Stats
| Current price | $7.85 | 52-week high | $12.05 |
| Prev. close | $7.68 | 52-week low | $6.15 |
| Day low | $7.60 | Volume | 6,100 |
| Day high | $8.07 | Avg. volume | 21,760 |
| 50-day MA | $8.64 | Dividend yield | N/A |
| 200-day MA | $8.84 | Market Cap | 65.70M |
Lumos Pharma, Inc. (LUMO) Company Bio
Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.
Latest LUMO News From Around the Web
Below are the latest news stories about Lumos Pharma Inc that investors may wish to consider to help them evaluate LUMO as an investment opportunity.
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2021 financial results after market close on Thursday, March 10, 2022. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. There will be a question-and-answer session f |
Great news for Lumos Pharma, Inc. (NASDAQ:LUMO): Insiders acquired stock in large numbers last yearIt is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it... |
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceAUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in |
Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ...Cambridge, MA, based Investment company Opaleye Management Inc. (Current Portfolio) buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics Pharmaceuticals Inc, Amicus Therapeutics Inc, Merus NV, sells ESSA Pharma Inc, Seres Therapeutics Inc, CM Life Sciences Inc, Lumos Pharma Inc, Kezar Life Sciences Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Opaleye Management Inc.. |
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a TurnaroundLumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
LUMO Price Returns
| 1-mo | -8.51% |
| 3-mo | -19.16% |
| 6-mo | 1.03% |
| 1-year | -25.10% |
| 3-year | -50.16% |
| 5-year | -93.30% |
| YTD | 13.28% |
| 2021 | -80.59% |
| 2020 | 56.83% |
| 2019 | 66.45% |
| 2018 | -81.26% |
| 2017 | -21.11% |
Loading social stream, please wait...